FDA Asks Stakeholders How To Cut Barriers To New Generic Drug Development
March 16, 2017
Less than a week after President Donald Trump called for FDA to eliminate red tape slowing the approvals of generic drugs in his plan to lower drug costs, FDA asks stakeholders to weigh in on how the agency can better support new generic development at a public workshop May 3. FDA specifically asks whether clarification of existing or the development of new guidances would help industry bring new generic drug products to market, and which generic drug regulatory science items...
Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting as the Trump administration and congressional Republicans take on the dismantling and replacement of the Affordable Care Act.